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Bo the Editor: Noncardiac surgery early after percutaneous coro-
ary intervention (PCI) with stenting has been associated with
dverse cardiac events in the perioperative period (1,2). However,
hese reports were on patients with bare-metal stents, did not
nclude drug-eluting stents, and did not compare patients who
ontinued their antiplatelet therapy during surgery with those who
nterrupted this therapy. Therefore, we conducted the current
tudy.
Patients who underwent noncardiac surgery between 1999 and
005 and had a successful PCI because of unstable coronary artery
isease within the 2 years before surgery were enrolled. The data
n PCI procedures were part of a prospectively maintained registry
ncluding a total of 574 procedures. Data on the surgical proce-
ure, as well as 30-day cardiovascular outcome, were retrospec-
ively collected by screening of medical charts. The medical ethics
ommittee of our hospital approved the study. All patients under-
ent PCI using either bare-metal or drug-eluting stents (paclitaxel
r sirolimus). Patient characteristics included the indication for
CI, the number of affected and stented coronary arteries, whether
he procedure was successful, left ventricular function, and medi-
ation use during and after PCI. In addition, cardiac risk factors
ere scored. Patients with bare-metal stents were prescribed
ifelong aspirin and clopidogrel for at least 1 month at the
iscretion of the treating physician (median 30 days, interquartile
ange 30 to 90 days). Patients with drug-eluting stents usually
eceived lifelong aspirin as well as clopidogrel for at least 3 months
sirolimus, median 90 days, interquartile range 60 to 180 days) to
months (paclitaxel, median 180 days, interquartile range 180 to
80 days), or longer at the discretion of the treating physician.
The surgical procedures were categorized according to surgical
isk, based on the definition of the Revised Cardiac Risk Index (3).
urthermore, the cardiac risk factors and medication use assessed
uring the initial PCI procedures were updated at the time of
peration and were used to assess the Revised Cardiac Risk Index
or each patient (3). Importantly, there was no protocol for
erioperative antiplatelet use in the population studied. Conse-
uently, some patients received aspirin and/or clopidogrel
hroughout the surgical procedure, whereas in other patients
spirin and clopidogrel were stopped 1 week before operation.
Medical charts were reviewed for the composite end points of
0-day major adverse cardiac events (MACE), defined as nonfatal
yocardial infarction and/or cardiac death as previously defined
ccording to guidelines of the American College of Cardiology/
uropean Society of Cardiology (4). Patients with an increased
ardiac risk (i.e., previous PCI) were routinely screened for
ostoperative cardiac end points using serial troponin T and
A
Tlectrocardiographic monitoring on days 1, 3, and 7 after surgery.
dditional tests were performed at the discretion of the treating
hysician. Blood loss during operation and the necessity and
uantity of perioperative transfusion requirements were noted in
ll patients.
aseline Characteristics of All Patients
Table 1 Baseline Characteristics of All Patients
n  192
Medical history
Ischemic heart disease 192 (100%)
Congestive heart failure 5 (3%)
Diabetes mellitus 47 (25%)
Renal impairment 29 (15%)
History of CVA or TIA 23 (12%)
Revised cardiac risk index
1 risk factor 65 (34%)
2 risk factors 74 (39%)
3 or more risk factors 53 (28%)
Medical therapy
Beta-blockers 131 (68%)
Statins 136 (71%)
Calcium antagonists 50 (26%)
Nitrates 20 (10%)
Diuretics 24 (13%)
ACE inhibitors 47 (24%)
Antiplatelet therapy during surgery 101 (53%)
Coronary stenting
Bare-metal 93 (48%)
Drug-eluting 99 (52%)
Number of vessels dilated
1 91 (47%)
2 60 (31%)
3 41 (21%)
Stenting successful 192 (100%)
Type of noncardiac surgery
Abdominal 31 (16%)
Vascular peripheral 30 (16%)
Eye 23 (12%)
Urologic 24 (13%)
Orthopedic 23 (12%)
Renal transplantation 12 (6%)
ENT 10 (5%)
Aortic 9 (5%)
Reconstructive 9 (5%)
Gynecologic 5 (3%)
Neurologic 4 (2%)
Carotid 3 (2%)
Other 9 (5%)CE  angiotensin-converting enzyme; CVA  cerebrovascular accident; ENT  ear/nose/throat;
IA  transient ischemic attack.
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January 2/9, 2007:122–5In total, 192 patients underwent surgery within 2 years after the
nitial PCI procedure (Table 1). Patients were arbitrarily divided in
n early-surgery group (defined as noncardiac surgery during
hich clopidogrel was required during the trials that led to
pproval of these devices and according to their labels: bare-metal
tents 1 month, sirolimus-eluting stents 3 months, paclitaxel-
luting stents 6 months) and a late-surgery group. Thirty patients
nderwent early surgery according to this classification.
During the first 30 postoperative days, 5 patients (2.6%) experi-
nced a MACE (all fatal, see Table 2 for characteristics of these
atients). In the early-surgery group, 4 MACEs (13.3%) occurred,
hereas in the late-surgery group, only 1 MACE (0.6%) occurred
Fisher exact test p  0.002) (Table 3). In 91 patients (47%),
ntiplatelet medication was interrupted during the perioperative
eriod. There was no significant difference in surgical risk between
atients in whom antiplatelet therapy (both clopidogrel and aspirin)
as interrupted versus those in whom antiplatelet therapy was
ontinued. The interruption was associated with a significantly higher
ncidence of MACE in patients who stopped versus those who
ontinued (5.5% vs. 0%, Fisher exact test p 0.023). In the group of
atients with a MACE, all 5 patients discontinued antiplatelet
herapy, whereas in the group without a MACE, only 46% (86 of
87) patients discontinued their antiplatelet therapy. In particular, in
atients in whom antiplatelet therapy was stopped before the required
ime for clopidogrel use (early-surgery group), the discontinuation of
ntiplatelet therapy had a detrimental effect: an incidence of MACEs
f 30.7% in the discontinuation group versus 0% in patients who
ontinued antiplatelet therapy (Fisher exact test p 0.026) (Table 4).
gain, all 4 patients with a MACE discontinued antiplatelet therapy,
hereas only 35% (9 of 26) of the patients without a MACE
iscontinued antiplatelet therapy.
There was no difference in the incidence of MACE between
atients with drug-eluting stents and those with bare-metal stents
2.2% vs. 3.0%, p 0.70); neither was there a significant difference
ithin the early-surgery group (28.6% for bare-metal stents and
.7% for drug eluting stents, p 0.23). Remarkably, in 57% of the
haracteristics of Patients With Perioperative Major Adverse Cardiac Events
Table 2 Characteristics of Patients With Perioperative Major Adverse C
Patient
Age
(yrs) Gender Type of Surgery Time From
A 58 M Abdominal 1
B 69 M Esophagectomy 28
C 64 M Abdominal 30
D 47 M ENT 80
E 65 M Urologic 253
Patient
A MI, thrombosis
B MI, thrombosis
C MI, left main th
D MI, thrombosis
E MI, thrombosis
CG electrocardiogram; ENT ear/nose/throat; LAD left anterior descending coronary artery;
ncidence of Nonfatal MI or Cardiac Death Within 30 Daysfter Noncardiac Surgery
Table 3
Incidence of Nonfatal MI or Cardiac Death Within 30 Days
After Noncardiac Surgery
Late Surgery (n  162) Early Surgery (n  30)
No MACE 161 (99.4%) 26 (86.7%)
MACE 1 (0.6%) 4 (13.3%)ACE  major adverse cardiac events; MI  myocardial infarction.
M
iatients with bare-metal stents, antiplatelet therapy was inter-
upted in the early-surgery group, whereas antiplatelet therapy was
nterrupted in 39.1% of the drug-eluting stent group.
Excessive blood loss during surgery was noted in the medical
harts of 2 patients (1 receiving antiplatelet therapy). Blood
ransfusion was required in 44 patients (24% vs. 20% for those who
ontinued vs. those who discontinued antiplatelet therapy, respec-
ively, p  0.50). In patients requiring blood transfusion, the
umber of units of homologues’ blood did not differ between those
ho continued versus those who discontinued antiplatelet therapy
median 2 vs. 3 U, p  0.51).
This study showed an association between early noncardiac
urgery after coronary artery stenting and perioperative adverse
ardiovascular events. Importantly, in patients undergoing early
urgery, discontinuation of antiplatelet therapy during the periop-
rative period may be a major cause of the increase in MACE. The
ype of stent (i.e., bare-metal or drug-eluting) did not influence
ardiovascular outcome in this cohort of patients.
In recent studies, an association between early noncardiac
urgery after PCI and adverse cardiac outcome has been reported
s well (1,2,5). However, these reports did not include the use of
rug-eluting stents. The excessive risk of early surgery after PCI
ight be attributable to the high risk of in-stent thrombosis during
he perioperative period. This thrombosis risk is possibly increased
y the stress response to major surgery. The stress response
ncludes sympathetic activation promoting shear stress on arterial
laques, enhanced vascular reactivity conducive to vasospasm,
educed fibrinolytic activity, platelet activation, and hypercoagula-
ility. Because procoagulant clotting factors increase while fibri-
olysis decreases, the surgical patient is in a hypercoaguable state.
urthermore, coronary stenting results in denudation of the
ndothelial surface. This might also contribute to the high risk of
atients with early surgery because re-endothelization takes up to
Events
Target Vessel Type of Stent
Aspirin
Withheld
Clopidogrel
Withheld
LAD Bare-metal Yes Yes
RCA, LCx Bare-metal Yes Yes
RCA Paclitaxel Yes Yes
RCA, LAD Sirolimus Yes Yes
LAD,RCA,LCx Paclitaxel Yes N/A
omplication
tent (angiography)
tent (autopsy)
sis, no stent thrombosis (autopsy)
tent (ECG)
tent (angiography)
eft circumflex artery; MImyocardial infarction; N/A not available; RCA right coronary artery.
ncidence of Nonfatal MI or Cardiac Death Within 30 Daysfter Noncardiac Surgery in P tients Wit Early (n  30)urg ry After PCI Who Either Continu d or Disco tinuedntiplatelet Therapy
Table 4
Incidence of Nonfatal MI or Cardiac Death Within 30 Days
After Noncardiac Surgery in Patients With Early (n  30)
Surgery After PCI Who Either Continued or Discontinued
Antiplatelet Therapy
Continued (n  17) Discontinued (n  13)
No MACE 17 (100%) 9 (69.3%)
MACE 0 (0%) 4 (30.7%)ardiac
PCI
C
LAD s
RCA s
rombo
LAD s
LAD sACE  major adverse cardiac events; MI  myocardial infarction; PCI  percutaneous coronary
ntervention.
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January 2/9, 2007:122–5weeks. This hypothesis is supported by our finding that all
ACEs in the early-surgery group occurred in patients in whom
ntiplatelet therapy was discontinued, including 3 events in the 17
atients with bare-metal stents in whom antiplatelet therapy was
iscontinued and 2 events in 9 patients with drug-eluting stents
ithout antiplatelet therapy. In contrast to our findings, Reddy
t al. (5) did not show an association between discontinuation of
ntiplatelet therapy and perioperative MACEs in 56 patients with
rior bare-metal stenting. This might have been attributable to the
mall number of events in their study.
The small number of events is also a limitation of the current
tudy. Multivariate analysis could not be performed because of this
mall number. However, the difference found between those
atients who continued their antiplatelet therapy and those who
id not deserves attention, and, until more evidence is available,
ntiplatelet therapy during surgery should be continued unless
here is an absolute contraindication.
laf Schouten, MD
on T. van Domburg, PhD
eroen J. Bax, MD, PhD
eter J. de Jaegere, MD, PhD
artin Dunkelgrun, MD
arm H. H. Feringa, MD
anne E. Hoeks, MSc
Don Poldermans, MD, PhD
he probability of coronary artery disease progression. Because
s
a
o
a
t
h
A
w
w
i
d
r
c
I
s
q
c
f
I
a
a
f
tErasmus Medical Center
r. Molewaterplein 40
015 GD Rotterdam
he Netherlands
-mail: d.poldermans@erasmusmc.nl
doi:10.1016/j.jacc.2006.10.004
lease note: Dr. Schouten is supported by an unrestricted research grant from The
etherlands Organization for Health Research and Development (ZonMw), the
ague, the Netherlands, and an unrestricted research grant from “Lijf & Leven”
oundation, Rotterdam, the Netherlands. Dr. Dunkelgrun is supported by an
nrestricted research grant (#2003B143) from the Netherlands Heart Foundation, the
ague, the Netherlands. Harold L. Dauerman, MD, served as Guest Editor for this
rticle.
EFERENCES
. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic
outcomes of noncardiac surgery soon after coronary stenting. J Am Coll
Cardiol 2000;35:1288–94.
. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients
undergoing non-cardiac surgery in the two months following coronary
stenting. J Am Coll Cardiol 2003;42:234–40.
. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and
prospective validation of a simple index for prediction of cardiac risk of
major noncardiac surgery. Circulation 1999;100:1043–9.
. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction
redefined—a consensus document of The Joint European Society of
Cardiology/American College of Cardiology Committee for the redef-
inition of myocardial infarction. J Am Coll Cardiol 2000;36:959–69.
. Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary
stenting. Am J Cardiol 2005;95:755–7.Letters to the Editorime Dependence
f Defibrillator Benefit
ostcoronary Revascularization
n a recent issue of the Journal,Goldenberg et al. (1), in a subgroup
nalysis of MADIT-II (Multicenter Automatic Defibrillator Im-
lantation Trial) (2), showed that in patients with ischemic left
entricular dysfunction who underwent coronary revascularization
CR), the efficacy of implantable cardioverter-defibrillator (ICD)
herapy was not apparent when the device was implanted 6 months
r less following CR. The authors concluded a time dependence of
he ICD therapy efficacy and raised the question of the optimal
iming of device implantation following CR. In our opinion, the
ssues raised by the study should instead focus on the reasons why
he ICD benefit was only apparent when implanted after long time
rames following revascularization.
In view of the elapsed time following CR by the time of
atient enrollment, we can assume that the distinguishing
eature between patients enrolled early and those enrolled late
fter CR resides in the probability of recurrent ischemia. This
as moreover the rationale of the selected time frames based oneveral observations suggest a role for silent (or overt) ischemia
s at least a contributing factor to sudden death (3,4), the lack
f survival benefit of ICD therapy in the group characterized by
lower probability of ischemia may therefore be attributed to
he prevention of recurrent ischemia by revascularization. This
ypothesis is further substantiated by the CABG (Coronary
rtery Bypass Graft)-Patch trial (5) where no survival benefit
as conferred by prophylactic ICD in patients undergoing CABG
ith depressed left ventricular function.
Accordingly, this subgroup analysis (1) further confirms the
mportance of revascularization to lower the risk of sudden cardiac
eath. As it is reasonable to first treat the contributing factors
ather than the consequences, a systematic evaluation of the
oronary artery status with CR if required prior to prophylactic
CD implantation should be the conclusion to draw from this
ubset of the MADIT-II study. The investigators raised the
uestion of the optimal timing of device implantation. However,
onsidering time frames from up to and more than 5 years
ollowing CR, the “timing” for a significant life-saving benefit of
CD to become apparent also coincides with an increasing prob-
bility of progression of coronary artery lesions. We may then
ssume that a substantial proportion of patients in these time
rames would actually have qualified for a coronary evaluation prior
o ICD implantation.
